We would love to hear your thoughts about our site and services, please take our survey here.
Mad, are you mad? Only joking.
Investors like myself have been diligently building stakes for the future, drawing confidence from the distinguished scientific work at the University of Manchester, especially the contributions of Professor Catherine O'Neill and Professor Andrew McBain. The addition of Stuart Ashman and Manprit Randhawa to our partnership team, known for their successful buy-build approach, promises exciting developments ahead, although the full impact of their efforts remains to be seen.
Setting aside the Croda/Sederma partnership, which in itself is a strong reason for long-term investment in SBTX, there's a need to address the clarity of our acquisition strategy as communicated in recent RNS announcements-something I made clear in our last interview. It's evident that there has been a shift in the timelines for our first acquisition from last year to the end of this calendar year. We have a basic understanding why-however, legalities prohib expansion until the time is right. An adjustment that has inadvertently affected investor confidence. Rebuilding this confidence will understandably take some time and greater transparency.
In the interim, and until there is more clarity on the strategy, I expected that some investors might adopt a cautious stance, while others might be considering the opportunity to invest post-calendar year-end, especially if our first acquisition extends into 2024. Delays in such processes, although frustrating, are not uncommon and can occur for a variety of reasons.
I have complete faith Stuart and Manprit will deliver the "transformative" result and fully intend to be fully invested for the eventuallity. That said, even my confidence has bruises.
It appears there might be a bit of misunderstanding regarding our M&A strategy. Stuart has provided clear guidance on this matter, so it's surprising that there's still some confusion. The strategy encompasses more than just augmenting AxisBiotix sales. It's also about enhancing our board's leverage in distribution agreement negotiations and reducing our dependency on hurried deal-making due to financial constraints. Acquiring companies with established products is a strategic move that saves time, money, and resources, while simultaneously securing growth and stability.
Do the math
https://twitter.com/LEMMINGINVESTOR/status/1735112193245348080
Sikhthetech aka stt1
I can rewrite the text as follows:
Don't hesitate to admit your mistakes. Since September/October 2014, you have been consistently wrong about the merits of your favourite company. We all make mistakes from time to time, but being wrong for 13 years is quite remarkable. It's a pity that you weren't short, that would have been really impressive.
#SPSY Spectra Systems' strategic acquisition of Cartor - a game-changer in high-security printing! Market cap soaring from £82M to £88.4M, reflecting confidence in this bold move. https://tinyurl.com/2mpmshs3
Unfortunately, when searching using the correct spelling of the products, no result!
https://www.amazon.co.uk/s?k=axisbiotix&crid=YYPVFDZ6JAQ8&sprefix=axisbiotix%2Caps%2C84&ref=nb_sb_noss_2
Psoriasis - again, no AxisBiotix listing
https://www.amazon.co.uk/s?k=psoriasis+treatment&crid=1CO6WKPO9YZ4G&sprefix=psoriasis+%2Caps%2C84&ref=nb_sb_ss_ts-doa-p_4_10
IMHO, it's must be on Prime otherwise it won't get noticed.
You’d need to be certifiable to trust Pfizer with what you of them since COVID.
Back to OPTI
https://is.gd/f3kyYU
TC,
It's unlikely that Croda would be concerned about anything regarding SBTX. They must have done their due diligence on SBTX and its board before signing any agreements. Their main goal is to introduce new and innovative products in the skincare market. The board of Croda has extensive experience and is well-versed in handling boardroom politics.
I understand that we have not started banking Croda/Sederma royalties yet. However, if we were to receive them, do you think we would be having a discussion about the salaries of the Board of Directors? I know the timing of this discussion is unfortunate, but there will come a time when all of the current concerns and frustrations will be forgotten and perhaps even forgiven if necessary.
BTW, Glancy, I kindly ask you not to mistake my role for that of TW, who is more of an activist, journalist, or investor. In contrast, I see myself more as a facilitator, investor, and researcher. Having said that, I did address investors' concerns by presenting them to SA. It's important to consider the historical context that has either been forgotten or is unknown. These will be come clear tomorrow.
Hi All,
I spoke with SA today and unfortunately, I am not feeling well enough to record a podcast. However, I do want to update you all over the weekend. Several critical points need to be clarified, such as SA's salary, how and why it was decided, and the decision-making process from both SA's & SOH's POV and my logic fact-checked and confirmed by SOH. I suggested a few objectives to SA, and I believe he listened, but only time will tell.
It seems that someone tried to get the FCA involved in my business over a mere £35, but their attempt was unsuccessful and littered with lies and errors. It's not the first time that we've had to deal with the FCA and NOMAD scrutinising our work, though. Back in 2008, two well-known journalists prompted them to investigate us, resulting in the removal of a single section that contained links to tips from Sunday papers. It's unfortunate that some individuals resort to such tactics, but we remain committed to running our business with integrity and transparency.
I bet the Weazel went on the HAMAS march!
Https://x.com/lemminginvestor/status/1729144431259840617?s=46
Bigpunt,
How about purchasing said products and backing IP INTO acquired products? Would this not be potentially attractive to MN partners? Would it not open discussion, for example, say, P&G or Unilever skin care products could be upgraded with science-backed IP? Cath and her team will be instrumental in assisting SA and Manprit in identifying what will work and what will not. Let's we how this develops.
In any event, going it alone will save millions and years in product development. If the strategy is to buy established brands with a customer base and an online presence, the option to back SBTX IP into the products improves the appeal. There are clues in the email that relate to what Croda are doing, much to some investor's frustration. The rewards arrive a little later.
There is a growing trend of savvy consumers demanding evidence.
See Sederma email today.
Derma-cosmetics : a growing segment in Personal Care
Take part in our webinar on derma-cosmetics on Tuesday 5th December at 11:30am (CET).
Our digital era has produced a significant shift in self-perception with people relating more to their digital image than to their reflection in the mirror. This shift has triggered a surge in non-invasive aesthetics medicine, especially within the younger e-generation.
At the same time, consumers are more and more savvy about cosmetic products compositions and their skin needs. They want to manage their routine in the best possible way with science backed, highly efficient and trusted ingredients.
The convergence of those two trends resulted is the emergence of derma-cosmetics. This product category is used to offer safe and gentle substitutes to aesthetics procedures or to complement treatments with pre and post applications.
During the webinar, our cosmetic actives and marketing experts will talk about the key drivers of derma-cosmetics, as well as the latest trends and solutions to develop high quality and effective skincare that meets the demands of today's consumers.
Bazza,
IMHO, TW overreacted to the email exchange. I am pretty sure SA did not intend to instruct TW how to such eggs. I have experience with TW how a minor disagreement can escalate, even when fun emojis have been used to illustrate humour.
TW can be abrasive, but he knows how to entertain his audience.
I finally listened to the bearcasts. He raised good points, but many were addressed in the chat I recorded. I still need clarity on one point.
TW is correct, and the playbook is a useful guide.
Currently, all we have is SA's assurance that any acquisition will increase earnings per share. However, it's important not to confuse this with a guaranteed deal. If the acquisition does not end up increasing earnings per share, SA will be held accountable. Personally, I have faith in SA's, Manprit's and the board's decision-making abilities. The first M&A is imminent, so, let us judge it on its merits.
IMHO, I think SBTX board's strategy will be vindicated. Moreover, the SA remuneration package (incorrectly inflated I may add) will be confined to history. I caveat this will a failure to deliver by Q1 adds weight to TW POS. I have faith as a useful idiot, an idiot running out of cash resources.
Hi TC,
I suggest avoiding focusing on a single company. Although I mentioned Derma, I also suggested considering alternatives as "potential" targets based on the SBTX strategy of buy/build. After searching for potential acquisitions based on likely value versus dilution, as mentioned in the update, the field narrowed down. Regarding the value of buying such a company, I believe it provides a ready-made market that SBTX can back its IP into, thus becoming attractive to potential MN commercial partners.
It has been a while since the comments, so, I cannot even remember the other potential target Companies. There are several down south, and importantly, the NE. I could be making a fool of myself, but most people know I am kite-flying.
Https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-466
Nick: To me, in hindsight, it was clear he wanted to create pre-placing share price-enhancing hype and leave it hanging that there might be transformational licencing news when there is no chance whatsoever.
Answer: I addressed this yesterday in the interview. Your opinion makes no sense for the reason I stated. It creates more problems due to the inflated discount on the “pump.” Nick: “Note the change to ‘early stage’ negotiations with regard to multinational deals.”
Answer: Again, I picked up on this and put this to him. Again, he clarified this. Nick: 2) “You asked him about funding in the first interview. He could have said we need to raise funds because we have the results coming and we would have the ‘going concern issue’ flagged up.”
Answer: No he could not. As per regulations, he must adhere to certain guidelines. Regardless, without a better understanding of the monthly cash flow situation, it was evident that funding was necessary before considering any M&A. As an investor, like many others, I anticipate that any such funding will be accompanied by options for CLN, debt, etc. Of course, if the answer was no, we are not intending to raise then yes, he could answer. Nick: 3) “He was in hype mode like he had never been before. He said he'd worked for multinational companies and been responsible for products with 100’s of millions of revenues but he’d never seen anything like what he had in front of him now. Really? So why buy a series of tiny cosmetic companies when one or two would do the job to roll out these potential hundreds of million revenue products he already has internally?”
Answer: When SA is saying; “never seen anything like what he had in front of him” I think he is referring to the science and the multiple opportunities across multiple platforms and potential commercial partners. We do not know the half of it. Dr Kelly gave us a hint, hence the excitement. It is becoming increasingly evident the Croda/Sederma partnership is much bigger than anticipated.
Nick: 4) I was aware that he wanted to do a small acquisition and maybe one or two very small bolt-ons. A decent enough strategy if it allows the likes of Axisbiotix-ps to be rolled out significantly through an acquired sales channel. The scale of the acquisitions disappointed me and raised a lot of questions about the strategy. Generally, I don’t like growth by acquisition, as TW says 70% of acquisitions fail. Look at a stock like Totally who attempted that approach. Aside from the risks it can create overhangs and haven’t investors experienced enough of that with the annual share price demise when OPTI decide to sell?
Answer: I generally agree with you and by default, Tom. I did state as much in the interview without labouring the point. We will have to wait and see what the first two are. I suspect a third will be much further down the track by which time I suspect, hope, and pray, Croda/Sederma royalties are dropping,
Nick I will attempt to address some of your comments respectfully. But firstly, I apologise if I have offended you. I didn’t name you, you have effectively outed yourself from the confines of a smaller group in the guild to a larger audience. I do so reluctantly because most of your observations, critiques, and concerns have already been addressed in yesterday's interview. It is a bit like Groundhog Day.
Nick: “Stuart isn’t at all confident of early Croda commercialisation hence the 12-month extension and accompanying plan for numerous acquisitions with the inevitable convertible loans that will go with that. The commercial deal with Croda hasn’t even been formalised yet as I understand it.
Answer: No, just plain wrong. SA had already addressed this in a previous interview back in October. If you choose not to believe him, that's another matter altogether. The extension was a legally required technicality, which has already been explained. As for the expected funding options and Croda's official commercial launch, we were already aware of them. Therefore, I fail to see any significant change that could have led to your change in opinion and attitude.
Let me spell out my reasons again. (OK, we do this dance again one more time :)Nick: 1) The first interview said there would be transformational news and he didn’t exclude multinational deals or other news. I think we can be pretty sure it is solely related to the first of many acquisitions and he left the prospect of a multinational deal as a disingenuous incitement for suckers like me to buy in.
Answer: I think we are more aligned here—transformation in 2024, not next week or next month. If you listened to yesterday's interview, SA confirmed one acquisition will be concluded BYE. That is part of the transformation context as I understand it, but a second acquisition looks to be required for the pieces to fit within the strategy.
Nick: In fact, he used ‘transformational acquisition’ in a subsequent RNS release. He had already announced an intention to acquire a company in previous announcements, so there is no reason why he could not have specified this was his reference to transformational. I even emailed him after, and he was equally vague.
Answer: Of course, he will be vague, were you expecting inside info? Nick: To me, in hindsight, it was clear he wanted to create pre-placing share price-enhancing hype and leave it hanging that there might be transformational licencing news when there is no chance whatsoever.
I want to respectfully inform you that the person, who was considered a "useful idiot", had actually warned individuals like you about the numerous challenges that DDDD was facing. These issues included being diluted to a great extent, which some people still expected to retain their £10 value, without acknowledging that the number of shares had increased fivefold. I distinctly remember that I was once called a "useless idiot" for bringing up these concerns.
Did you happen to listen to yesterday's interview? If the answer is yes, could you please share examples of my ignorance? I was merely asking questions that investors were seeking answers to. Does that make them foolish, idiots? Apparently, at least two of them are.